Posted by Michael Wonder on 09 Jan 2026
Alessa Therapeutics announces FDA fast track designation for Enolen, a first of its kind treatment for localised prostate cancer
8 January 2026 - Alessa Therapeutics today announced that the US FDA has granted fast track designation for Enolen, the Company’s lead product candidate for the treatment of low to intermediate risk, localised prostate cancer.
Enolen utilises novel anti-androgen eluting implants containing the FDA approved prostate cancer compound enzalutamide.
